The Activity of Liposomal Linolenic Acid Against *Helicobacter pylori* In Vitro and Its Impact on Human Fecal Bacteria

Ya Wang¹,²†, Shuang Wu¹†, Le Wang¹†, Youhua Wang¹, Dongsheng Liu¹, Yingjun Fu² and Yong Xie¹*

¹ Key Laboratory of Digestive Diseases of Jiangxi, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China, ² School of Pharmacy, Nanchang University, Nanchang, China

*Correspondence: Yong Xie
xieyong_tishoncu163.com
†These authors have contributed equally to this work and share first authorship

**INTRODUCTION**

*Helicobacter pylori* (H. pylori) infection can cause a series of gastrointestinal diseases, including chronic gastritis, peptic ulcers, and gastric cancer (Schlaermann et al., 2016). In addition, studies have proven that some extragastric diseases, such as iron-deficiency-related anemia and vitamin B12 deficiency, are also associated with *H. pylori* infection (Ražuka-Ebela et al., 2018). Successful...
eradication of *H. pylori* can reduce the risk of related diseases and benefit patients to varying degrees. A study showed that among *H. pylori*-positive duodenal ulcer patients, the recurrence rate of gastric ulcers and duodenal ulcers in patients receiving *H. pylori* eradication therapy was significantly lower than that in patients who did not receive eradication therapy (Ford et al., 2016). In addition, eradication of *H. pylori* can also prevent indigestion and other symptoms (Moayyedi et al., 2017). Currently, the recommended *H. pylori* eradication therapy is the quadruple therapy consisting of a bismuth agent and a proton pump inhibitor (PPI) combined with two antibacterial drugs in China (Malfetherine et al., 2017; Liu et al., 2018). The two antibacterial drugs used in this combination include amoxicillin (AMX), metronidazole (MTZ), levofloxacin (LVFX), clarithromycin (CAM), tetracycline and furazolidone. With the increasing resistance of *H. pylori* to antibacterial drugs, especially MTZ, LVFX and CAM (Zhang, 2015; Savoldi et al., 2018), the optimal overall eradication rate of *H. pylori* is difficult to reach (Graham et al., 2007). In addition, frequent adverse reactions and poor patient compliance also result in therapy failure. The use of PPIs and antibiotics may also disturb the intestinal flora (Hsu et al., 2018). To solve these problems, the study of effective non-antibiotics has become a research hotspot.

Linolenic acid (LLA) is a polyunsaturated fatty acid. Studies have shown that LLA could inhibit the proliferation of *H. pylori* *in vitro* but not *in vivo*, possibly because of the low solubility of LLA and its tendency to oxidize, esterify, and form complexes with lipoproteins *in vivo* (Jung and Lee, 2016). To overcome this challenge, LLA was packed into liposome, and the liposomal LLA (*LipoLLA*) prepared thereby showed good anti-*H. pylori* activity (Obonyo et al., 2012; Thamphiwatana et al., 2014).

In this study, we further elucidated the combined effects of *LipoLLA* with AMX, MTZ, LVFX and CAM. Meanwhile, the effects of pH and time on the bactericidal effect of *LipoLLA* were studied. As well, we evaluated the effect of *LipoLLA* on the outer membrane barrier of *H. pylori*. We have also discussed the effects of *LipoLLA* on probiotics and the human intestinal flora to provide a theoretical basis for the efficacy and safety of *LipoLLA* as an *H. pylori* eradication therapy in the future.

**MATERIALS AND METHODS**

**Preparation of LipoLLA**

*LipoLLA* was prepared by a standard vesicle extrusion method as previously described (Thamphiwatana et al., 2014). Briefly, phospholipids, cholesterol and LLA were mixed in a weight ratio of 6:1:3 (total weight of 16 mg), and dissolved in chloroform (4 mL). Then chloroform was evaporated to form a thin layer of lipid. After hydration, vortexing and sonication, the resulting lipid vesicles were extruded by microextruder through a polycarbonate membrane with a pore size of 100 nm. Following, remove unloaded LLA and sterilize through a 0.22 μm filter. Finally, the hydrodynamic size and surface zeta-potential of liposomes were measured to ensure the stability. The prepared *LipoLLA* were stored at 4°C.

**Bacterial Strains**

The *H. pylori* strains ATCC43504 (NCTC11637) and SS1 and thirty clinical isolates were obtained from the Department of Gastroenterology, The First Affiliated Hospital of Nanchang University. The research protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (IRB 2018-116). *Lactobacillus* *BG*-2-2 and *Bifidobacterium* WBIN03 were kindly provided by Professor Wei Hua, Sino German Joint Research Institute, Nanchang University. *H. pylori* strains were maintained on Campylobacter agar base (OXOID, UK) plates supplemented with 5% sheep blood under microaerobic conditions (5% O2, 10% CO2, and 85% N2) at 37°C for 2–3 days. The *Lactobacillus* strain was grown in MRS medium (Solarbio Technology Co., LTD, Beijing, China) under anaerobic conditions. The *Bifidobacterium* strain was grown in MRS medium containing 0.05% L-cysteine hydrochloride monohydrate under anaerobic conditions.

**The Minimum Inhibitory Concentrations (MICs) of LipoLLA and Antimicrobial Agents Against *H. pylori***

The MICs of *LipoLLA* and four antibiotics (AMX, MTZ, LVFX and CAM) against *H. pylori* were detected by the agar dilution method according to the Clinical and Laboratory Standards Institute (Cockerill, 2012). Briefly, serial 2-fold dilutions of the drugs were prepared in Mueller-Hinton agar. The bacteria were harvested, resuspended in 1 mL of physiological saline, and adjusted to an optical density at 600 nm of 1x10^7-1x10^8 colony forming unit (CFU)/mL. Then 10 μL of the test bacterial suspension was inoculated on the plate at 37°C under microaerobic conditions for 72 h. ATCC43504 was used as quality control strain. The MIC value was the lowest concentration that led to complete inhibition of bacterial growth compared with the blank control group. The resistance of the strains to the four antibiotics was determined: AMX≥1 μg/mL, MTZ≥ 8 μg/mL, LVFX≥1 μg/mL, and CAM≥1 μg/mL.

**Combined Effects of LipoLLA and Four Antimicrobial Agents**

According to the MIC value of each drug when used alone, the chessboard method was used to design the concentration combinations of *LipoLLA* with AMX, MTZ, LVFX and CAM and to determine the MIC values for combined use (Odds, 2003). Serial 2-fold dilutions of *LipoLLA* with the four antibiotics were mixed in a 1:1 ratio in Mueller-Hinton agar. Then the bacteria were similarly prepared as test suspension and incubated on the agar at 37°C under microaerobic conditions for 72 h before determining MICs. The combinatorial effect was determined by the fractional inhibitory concentration index (FICI) (Isenberg, 1992).

\[
\text{FICI} = \frac{\text{MIC}_{A1}}{\text{MIC}_{A2}} + \frac{\text{MIC}_{B1}}{\text{MIC}_{B2}}
\]

Where MIC\(_{A1}\) is the MIC of *LipoLLA* combined with antibiotics; MIC\(_{A2}\) is the MIC of *LipoLLA* alone; MIC\(_{B1}\) is the MIC of antibiotics combined with *LipoLLA*; and MIC\(_{B2}\) is the...
MIC of antibiotics alone. When FICI ≤ 0.5, the combinatorial effect of two drugs was defined as synergistic; when 0.5<FICI ≤ 1, the effect was defined as additive; when 1<FICI ≤ 2, the effect was defined as irrelevant; and when FICI>2, the combinatorial effect was defined as antagonistic (Shang et al., 2019).

Concentration Sterilization Curve of LipoLLA Against H. pylori

Eight strains of H. pylori with different drug resistance properties (SS1, sensitive strain, MTZ-resistant strain, LVFX-resistant strain, CAM-resistant strain, dual drug-resistant strain, triple drug-resistant strain, and quadruple drug-resistant strain) were used in this study. H. pylori cells were harvested, and the concentration was adjusted to an optical density at 600 nm of 5×10⁶ CFU/mL, then inoculated into Brucella broth containing 5% (vol/vol) fetal bovine serum (FBS) mixed with different concentrations of LipoLLA at 37°C under microaerobic conditions for 18 h. A series of 10-fold dilutions of the bacterial suspension was prepared, and 100 µL from each diluted sample was inoculated onto a Campylobacter agar base plate supplemented with 5% sheep blood. The plates were cultured in an incubator for 72 h before the number of viable colonies was counted.

Influence of pH and Time on the Bactericidal Effect of LipoLLA

To research the influence of pH on the anti-H. pylori effect of LipoLLA, Brucella broth was adjusted to different solutions at pH 5, 6, and 7 respectively by using concentrated hydrochloric acid. SS1 and a multidrug-resistant strain (MDR2) were used. The bacteria cells were harvested and adjusted to an optical density at 600 nm of 5×10⁶ CFU/mL, then inoculated into Brucella broth containing 5% (vol/vol) fetal bovine serum (FBS) mixed with different concentrations of LipoLLA at 37°C under microaerobic conditions for 18 h. After that, a series of 10-fold dilutions of the bacterial suspension was prepared, and 100 µL from each diluted sample was inoculated onto a Campylobacter agar base plate supplemented with 5% sheep blood. The plates were cultured in an incubator for 72 h before the number of viable colonies was counted. Time-kill assay was performed to explore the impact of time on the bactericidal effect of LipoLLA. SS1 was co-cultured with LipoLLA in the same way as above. Then liquid cultures of LipoLLA with different concentrations and SS1 were diluted and inoculated on solid medium at different time points (0 h, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h) for 72 h. The number of viable colonies was counted to obtain the time sterilization curves with different concentrations of LipoLLA.

Effect of LipoLLA on the Outer Membrane Barrier and Ultrastructure of H. pylori

SS1 was inoculated into Brucella broth containing 5% (vol/vol) FBS and cultured with LipoLLA (7.5 µg/mL) for 24 h. Then, the bacteria were harvested by centrifugation at 3000 rpm for 10 min, and the contents of GLU and AST in the supernatant were detected by an automatic biochemical analyzer (HITACHI, Japan) to study the effect of LipoLLA on the outer membrane barrier of H. pylori. The remaining pellets treated with LipoLLA (7.5 µg/mL) were prepared for observing the ultrastructure of the strain by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Briefly, pellets were fixed with 2% glutaraldehyde for 2 h at room temperature. The SEM samples were post fixed with 1% osmium acid in phosphate buffer (0.1 M, pH 7.4), dehydrated, dried by critical point drier (Quorum, K850, UK), and then sprayed with gold over 30 s by carbon coater (IXRF, MSP-2S, USA) before SEM (HITACHI, SU8100, Japan) imaging. To prepare the TEM samples, the fixed bacteria were resuspended in 1% agarose after centrifugation, then post fixed with 1% osmium acid in phosphate buffer (0.1 M, pH 7.4) for 2 h; After dehydration, infiltration and embedding, ultramicrotome (Leica, Leica UC7, Germany) was used for slicing to 60-80 nm sections, and then dried overnight after double-staining with uranium lead. Finally, sections were examined by TEM (HITACHI, HT7700, Japan).

Bactericidal Effect of LipoLLA on Probiotics

Lactobacillus strain BG-2-2 and Bifidobacterium WBIN03 were used in this part of study. Bacteria were harvested, and the concentration was adjusted to an optical density at 600 nm of 5×10⁶ CFU/mL. Then, the strains were inoculated into MRS broth (the Bifidobacterium strain was grown in MRS medium containing 0.05% L-cysteine hydrochloride monohydrate) mixed with different concentrations of LipoLLA, grown at 37°C under anaerobic conditions (an anaerobic jar and immediately put in an anaerobic bag) for 18 h. Then a series of 10-fold dilutions of the bacterial suspension was prepared, and 100 µL from each diluted sample was inoculated onto an MRS solid medium (0.05% L-cysteine hydrochloride monohydrate was supplemented for the strain WBIN03). The plates were cultured in an incubator for 72 h before the number of viable colonies was counted.

Effect of LipoLLA on Human Fecal Flora

The research protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (IRB 2014-032). And the participant provided written informed consent to participate in this study. The feces of a male, 25 years old, healthy volunteer were collected, stirred with normal saline (add 200 mL saline to every 50 g of feces), then filtered, and centrifugated at 3000 rpm for 5 minutes. Repeating the above filtration and centrifugation, and the obtained mixture were divided into four groups to receive different treatment (n=3, V=20 mL) for the following treatment: the blank control group, the LipoLLA (7.5 µg/mL) group, the AMX (1 µg/mL) group, and the CAM (1 µg/mL) group. All four groups were incubated at 37°C under anaerobic conditions for 24 h. Then centrifuged at 3000 rpm for 5 minutes to obtain the precipitate and placed in a liquid nitrogen environment for 20 min. Finally, samples were all immediately stored in sterile containers and frozen at -80°C until RNA extraction. RNA was extracted using the E.Z.N.A.® Soil RNA Midi Kit and transcribed to cDNA with HiScript® II Q RT SuperMix for qPCR (+gDNA wiper) for polymerase chain
reaction (PCR) amplification. The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified with the primers 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3') by a thermocycling PCR system (GeneAmp 9700, ABI, USA). The resulting PCR products were purified using the AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA) and quantified using QuantiFluor™-ST (Promega, USA). Purified amplicons were pooled in equimolar amounts and subjected to paired-end sequencing on an Illumina MiSeq platform (Illumina, San Diego, USA) according to the standard protocols recommended by Majorbio Bio-Pharm Technology Co., Ltd. (Shanghai, China).

**Statistical Analysis**

Logarithms of the MIC values were taken when LipoLLA, AMX, MTZ, LVFX and CAM were used alone or in combination against H. pylori. Student’s t test was used when the difference between groups was normally distributed; otherwise, the Wilcoxon symbol rank sum test was used. One-way analysis of variance was used to compare more than two groups. P ≤ 0.05 was considered statistically significant.

**RESULTS**

**Antibacterial Effect of LipoLLA on H. pylori**

As a quality control strain, MICs of ATCC43504 to four antibacterial drugs AMX, MTZ, LVFX and CAM were all within the quality control range according to CLSI (Supplementary Table S1), which proved the experimental results to be reliable. The MICs of LipoLLA and four antibiotics against 30 H. pylori strains are shown in Table 1. Five strains were sensitive to all four antibiotics (S1-S5), 6 strains were resistant to MTZ (MTZ1-MTZ6), 5 strains were resistant to LVFX (LVFX1-LVFX5), 5 strains were resistant to CAM (CAM1-CAM5), 3 strains exhibited dual drug resistance (DR1-DR3), and 6 strains were multidrug resistant (MDR1-MDR6). For all these strains, the range of the MIC of LipoLLA was 3.75-15 μg/mL, and there was no difference between susceptible and resistant strains (P>0.05). The combined effects of LipoLLA and the four antibiotics were tested on these 30 clinical isolates. According to the FICIs, LipoLLA significantly lowered the MICs of AMX, MTZ, LVFX and CAM against H. pylori. In these 30 H. pylori strains, the synergistic effect of LipoLLA combined with AMX was 100% (Supplementary Table S2).

| strains | LipoLLA | AMX | MTZ | LVFX | CAM |
|---------|---------|-----|-----|------|-----|
| S1      | 7.500   | 0.016 | 1.000 | 0.250 | 0.063 |
| S2      | 7.500   | 0.016 | 1.000 | 0.125 | 0.063 |
| S3      | 7.500   | 0.016 | 4.000 | 0.032 | 0.125 |
| S4      | 7.500   | 0.016 | 1.000 | 0.032 | 0.063 |
| S5      | 7.500   | 0.032 | 2.000 | 0.250 | 0.063 |
| MTZ1    | 7.500   | 0.016 | 8.000 | 0.032 | 0.063 |
| MTZ2    | 7.500   | 0.063 | 16.000 | 0.125 | 0.063 |
| MTZ3    | 7.500   | 0.032 | 32.000 | 0.250 | 0.500 |
| MTZ4    | 7.500   | 0.016 | 32.000 | 0.250 | 0.063 |
| MTZ5    | 7.500   | 0.016 | 128.000 | 0.250 | 0.063 |
| MTZ6    | 7.500   | 0.016 | 256.000 | 0.250 | 0.063 |
| LVFX1   | 15.000 | 0.032 | 0.500 | 32.000 | 0.125 |
| LVFX2   | 7.500   | 0.016 | 4.000 | 128.000 | 0.063 |
| LVFX3   | 15.000 | 0.016 | 2.000 | 128.000 | 0.063 |
| LVFX4   | 15.000 | 0.016 | 4.000 | 128.000 | 0.016 |
| LVFX5   | 7.500   | 0.016 | 1.000 | 128.000 | 0.063 |
| CAM1    | 7.500   | 0.032 | 2.000 | 0.125 | 8.000 |
| CAM2    | 7.500   | 0.032 | 2.000 | 0.250 | 8.000 |
| CAM3    | 7.500   | 0.016 | 2.000 | 0.063 | 256.000 |
| CAM4    | 7.500   | 0.016 | 2.000 | 0.125 | 256.000 |
| CAM5    | 7.500   | 0.016 | 2.000 | 2.000 | 1.000 |
| DR1     | 7.500   | 0.016 | 2.000 | 0.250 | 1.000 |
| DR2     | 3.750   | 0.016 | 8.000 | 1.000 | 0.063 |
| DR3     | 7.500   | 0.016 | 32.000 | 1.000 | 8.000 |
| MDR1    | 3.750   | 0.016 | 8.000 | 128.000 | 8.000 |
| MDR2    | 7.500   | 0.016 | 32.000 | 128.000 | 8.000 |
| MDR3    | 7.500   | 0.016 | 32.000 | 32.000 | 8.000 |
| MDR4    | 7.500   | 0.063 | 32.000 | 2.000 | 16.000 |
| MDR5    | 7.500   | 0.125 | 256.000 | 128.000 | 8.000 |
| MDR6    | 7.500   | 1.000 | 256.000 | 128.000 | 256.000 |

The MICs of 30 clinically isolated H. pylori strains were determined. 5 sensitive strains (S1-S5), 6 MTZ-resistant strains (MTZ1-MTZ6), 5 LVFX- resistant strains (LVFX1-LVFX5), 5 were CAM-resistant strains (CAM1-CAM5), 3 dual drug-resistance strains (DR1-DR3), and 6 multidrug resistant strains (MDR1-MDR6). MIC, minimum inhibitory concentration; AMX, amoxicillin; MTZ, metronidazole; LVFX, levofloxacin; CAM, clarithromycin; S, sensitive strain; DR, dual drug-resistant strain; MDR, multidrug-resistant strain.
and the MICs of the two antibacterial agents against *H. pylori* were significantly decreased (P<0.001) (Figure 1A). When LipoLLA was combined with MTZ, one strain (3.3%) showed an additive effect, and the others (96.7%) showed a synergistic effect (Supplementary Table S3); the MICs decreased significantly (P<0.001) (Figure 1B). All 30 tested strains showed synergistic effects when LipoLLA was combined with LVFX (Supplementary Table S4), and there were significant

![Figure 1](image-url)
differences in MIC reduction after combined use (P<0.001) (Figure 1C). After CAM was used in combination with LipoLLA, four strains (13.3%) showed additive effects, and the others (86.7%) showed synergistic effects (Supplementary Table S5). The differences in MIC values before and after combined use were still significant (P<0.001) (Figure 1D). All of these results indicated that LipoLLA had synergistic anti-\textit{H. pylori} effects when combined with AMX, MTZ, LVFX and CAM in vitro.

### Concentration Sterilization Curve of LipoLLA Against \textit{H. pylori}

To investigate the bactericidal ability of LipoLLA against \textit{H. pylori}, bactericidal activity curves were prepared for 8 of the tested strains (SS1, sensitive strain S3, MTZ-resistant strain MTZ6, LVFX-resistant strain LVFX1, CAM-resistant strain CAM2, dual drug-resistant strain DR1, triple drug-resistant strain MDR2, and quadruple drug-resistant strain MDR4) (Figure 2). After
treatment with LipoLLA at different concentrations for 18 h, the number of colonies of the SS1 strain, sensitive strain and drug-resistant strains decreased to some extent. When the concentration of LipoLLA increased to 15 µg/mL, no colony growth was observed, suggesting that LipoLLA had a good bactericidal effect on both sensitive and drug-resistant strains of H. pylori.

Influence of pH and Time on the Bactericidal Effect of LipoLLA

To explore the effect of pH on the bactericidal effect of LipoLLA, we generated a concentration-bactericidal curve for LipoLLA with SS1 and the clinical multidrug-resistant strain MDR2 under different pH values. For SS1, no colony growth was observed when the concentration of LipoLLA reached 15 µg/mL at pH 7; when the concentration of LipoLLA reached 7.5 µg/mL at pH 6 or 5, there was no colony growth, which was significantly different from the result at pH 7 (P<0.05) (Figure 3A). For MDR2, no colony growth was observed when the concentration of LipoLLA reached 15 µg/mL at pH 7; when the concentration of LipoLLA reached 3.75 µg/mL at pH 5, no colony growth occurred, and when the concentration reached 7.5 µg/mL at pH 6, no colony growth occurred, which was significantly different from the result at pH 7 (P<0.05) (Figure 3B). These results suggested that LipoLLA can completely kill H. pylori at a lower concentration at pH 5 or 6 than at pH 7. The time-sterilization curve showed that with the extension of treatment time, the number of viable bacterial colonies decreased gradually.

The higher the drug concentration was, the faster the number of viable bacterial colonies decreased (Figure 3C). In particular, when the LipoLLA concentration increased to 7.5 µg/mL and 15 µg/mL, the bacterial colonies were completely destroyed after 24 h. These results suggested that the killing effect of LipoLLA on H. pylori was time and concentration dependent and that LipoLLA had a better effect on H. pylori in a moderately acidic environment.

Effect of LipoLLA on the Outer Membrane Barrier and Ultrastructure of H. pylori

The bactericidal mechanism of LipoLLA was explored by content leakage assessment as well as bacterial morphology observation. After treatment with LipoLLA for 24 h, the GLU content in the supernatant of SS1 was significantly increased compared with that in the control group (P<0.05) (Figure 4A). The AST content was also significantly higher than that in the control group (P<0.01) (Figure 4B). SEM was used to observe the obvious atrophy and adhesion of SS1 bacteria treated with LipoLLA, which was significantly different from the normal morphology (Figure 4C). TEM showed that the cell wall of SS1 in the control group was closely connected with the cell membrane, and the cytoplasmic structure was dense, with flagella faintly visible. After treatment with LipoLLA, the outer membrane of SS1 was seriously damaged with an unclear structure, and the cytoplasmic contents were sparse or disappeared (Figure 4D). These results indicated that LipoLLA destroyed the outer membrane barrier and ultrastructure of H. pylori.
Bactericidal Effect of LipoLLA on Probiotics

*Lactobacillus* BG-2-2 and *Bifidobacterium* WBIN03 were tested to explore the effect of LipoLLA on probiotics. The bactericidal curves showed that the number of viable bacteria of the two strains was on the same order of magnitude as that of the control group when the concentration of LipoLLA increased. When the concentration of LipoLLA increased to 30 μg/mL (at which point *H. pylori* could no longer grow), the number of viable bacteria of *Lactobacillus* BG-2-2 was 2.497 ± 0.266 x10^9 CFU/mL, which

![FIGURE 4](image_url)

*FIGURE 4* | Effect of LipoLLA on the outer membrane barrier and ultrastructure of *H. pylori*. Levels of aspartate aminotransferase (A) and glucose (B) in SS1 supernatant after LipoLLA treatment; *P < 0.05; **P < 0.01. Scanning electron microscopy images of SS1 after LipoLLA treatment (C). Transmission electron microscopy images of SS1 after LipoLLA treatment (D). Scale bars represent 5 μm and 1 μm respectively.
was not significantly different from that in the control group (3.123 ± 0.464 ×10⁹ CFU/mL) and at other concentrations (P>0.05) (Figure 5A). The viable count of Bifidobacterium WBIN03 was 8.850 ± 2.486 ×10⁷ CFU/mL at a LipoLLA concentration of 30 µg/mL, which was not significantly different from that in the control group (1.283 ± 0.179 ×10⁸ CFU/mL) and at other concentrations (P>0.05) (Figure 5B). These indicated that LipoLLA had no significant effect on L. rectale group was close to the control group (P=0.040) were significantly enriched in the control group. Together, these findings indicated that LipoLLA caused few significant changes in the human intestinal flora. These results provide the possibility for LipoLLA to be used as a safe anti-H. pylori agent.

**DISCUSSION**

*H. pylori* infection remains a difficult challenge worldwide, especially in some developing countries (Hooi et al., 2017). Antibiotic regimens have been modified continuously to overcome drug resistance, but the results remain unsatisfactory (Song et al., 2016; Tariq et al., 2020). Obviously, the discovery of an effective *H. pylori* eradication therapy would have global significance. In our study, LipoLLA showed favorable anti-*H. pylori* activity *in vitro* and exhibited little interference with human fecal bacteria.

LipoLLA was prepared by packing LLA into nanoliposomes to overcome the poor hydrophilicity of LLA. As a common drug delivery system, liposomes are deemed to be safe for humans. The liposome formulation can fuse with the cell membrane more stably and deliver LLA to the membrane with less interference with the intracellular pathway than free LLA. Thamphiwatana
Thamphiwatana et al. (2014) found that LipoLLA could reduce colonization by *H. pylori* in mice and ameliorate inflammation, but its antibacterial effect on clinical strains of *H. pylori* was not clear. Our results showed that the MICs of LipoLLA against 30 *H. pylori* clinical isolates were 3.75-15 mg/mL, regardless of whether the strains were sensitive to AMX, MTZ, LVFX and CAM or resistant. LipoLLA showed great antibacterial activity. At present, there is no well-developed monotherapy for *H. pylori* infection. Therefore, according to the MIC of each strain, we determined the combined effect of LipoLLA with AMX, MTZ, LVFX and CAM based on FICI values. The results showed that the MICs of LipoLLA, AMX, MTZ, LVFX and CAM against the 30 clinical isolates of *H. pylori* were all significantly reduced, and the combined effect was synergistic or additive. This provides a basis for the development of a combined antibacterial regimen.

(Thamphiwatana et al., 2014) found that LipoLLA could reduce colonization by *H. pylori* in mice and ameliorate inflammation, but its antibacterial effect on clinical strains of *H. pylori* was not clear. Our results showed that the MICs of LipoLLA against 30 *H. pylori* clinical isolates were 3.75-15 mg/mL, regardless of whether the strains were sensitive to AMX, MTZ, LVFX and CAM or resistant. LipoLLA showed great antibacterial activity. At present, there is no well-developed monotherapy for *H. pylori* infection. Therefore, according to the MIC of each strain, we determined the combined effect of LipoLLA with AMX, MTZ, LVFX and CAM based on FICI values. The results showed that the MICs of LipoLLA, AMX, MTZ, LVFX and CAM against the 30 clinical isolates of *H. pylori* were all significantly reduced, and the combined effect was synergistic or additive. This provides a basis for the development of a combined antibacterial regimen.
Our study demonstrated that the bactericidal effect of LipoLLA on *H. pylori* was time and concentration dependent and that LipoLLA had a favorable effect on *H. pylori* in a moderately acidic environment. This finding suggested that LipoLLA may be more stable in acidic environments and are suitable for functioning in the stomach. The time dependence of LipoLLA indicates the optimal interval and dosage for clinical application.

Studies have reported that the antibacterial action of free fatty acids targets the cell membrane of bacteria, interfering with the production of bacterial energy by destroying electron transfer chains and oxidative phosphorylation, inhibiting enzyme activity, blocking nutrient absorption, producing peroxide and autooxidation-related degradation products, or directly lysing bacteria (Desbois and Smith, 2010). In our study, we detected the AST content, which is often used as an indicator of changes in bacterial plasma membrane permeability (Zhang et al., 2016), as well as GLU in the supernatant of *H. pylori* after LipoLLA treatment. The increased levels of AST and GLU indicated that the structure of the *H. pylori* plasma membrane and outer membrane was destroyed. In addition, the LipoLLA formulation with a size of ~100 nm had enough surface tension to fuse with the cell membrane, and the phospholipid bilayer structure protected LLA from degradation to enhance the survival of normal probiotics.

The ultrastructural changes in *H. pylori* treated with LipoLLA observed by SEM and TEM showed an atrophied and damaged membrane. It was further confirmed that the special liposome structure made it easy for LipoLLA to fuse with the bacterial membrane and damage the integrity of the membrane, which caused exudation of the bacterial contents and finally resulted in bacterial death. Compared with the action of conventional antibiotics, this anti-*H. pylori* mechanism of LipoLLA was capable of reducing the induction of bacterial drug resistance (Petschow et al., 1996; Thamphiwatana et al., 2014). This feature made LipoLLA strongly destructive against *H. pylori*. LipoLLA produces improved antibacterial effects when used alone, and when used in combination with other antibacterial drugs, the destruction of the outer membrane barrier could also help the other drugs rapidly enter the bacteria, thereby enhancing the antibacterial effect. This may explain why the effects of LipoLLA combined with AMX, MTZ, LVFX, and CAM were synergistic or additive in this study.

Thamphiwatana and colleagues incubated the adenocarcinoma gastric cell line (AGS) with LipoLLA, and reported that there was a negligible release of lactate dehydrogenase, which assessed cell death (Thamphiwatana et al., 2014). And after five consecutive days of administration of LipoLLA in mice, there was no significant change in body weight, stomach tissue section showed no apparent increase in gastric epithelial apoptosis (Thamphiwatana et al., 2014). These results suggested little toxicity of LipoLLA to normal cells when acting against *H. pylori*.

Li found that LipoLLA poses much less effect on the composition and diversity of gastrointestinal microbiota in mice than triple therapy (PPI, AMX and CAM) and therefore has fewer side effects (Li et al., 2018). The impact of the intestinal flora on human health has received increasing attention. Drugs may affect the normal gut flora as well as bacterial resistance (Ianiero et al., 2016; Jackson et al., 2016). Increased levels of drug-resistant bacteria in the intestinal flora could lead to the transfer of resistance genes to pathogenic bacteria and commensal bacteria through horizontal gene transfer, in turn leading to the failure of antimicrobial therapy (Oh et al., 2016). Four years after CAM and MTZ treatment, high level of the macrolide resistance gene *erm (B)* were found, indicating the antibiotic resistance (Jakobsson et al., 2010). While epidemic spread of *erm* (B) has been shown to be the cause of increased macrolide resistance in *Streptococcus pyogenes*. *H. pylori* develops resistance to CAM through point mutation, which clearly affects the efficacy of regimens and determines the first-line treatments of choice (Flores-Treviño et al., 2018). *H. pylori* isolated from patients who later failed the triple therapy showed a greater resistance to CAM. In this study, the concentration-bactericidal curves showed that LipoLLA had no significant effect on the proliferation of *Lactobacillus* BG-2-2 and *Bifidobacterium* WBI03 when the concentration was 0-30 μg/mL, indicating that LipoLLA effectively killed *H. pylori* without affecting the survival of normal probiotics.

Then, 16S rRNA sequencing demonstrated that LipoLLA has no significant effect on the diversity and species composition of the intestinal flora, indicating that the use of LipoLLA as a potential anti-*H. pylori* drug guarantees for the safety of the intestinal flora to a certain degree. The alpha diversity analysis of 16S rRNA sequencing results showed no change in bacterial species after drug treatments. This is not consistent with previous studies in which AMX or CAM treatment led to a decrease in bacterial diversity (Langdon et al., 2016). The reason may be that the concentration of AMX and CAM that we used was 1 μg/mL, which was constant *in vitro* and did not reach the concentration level that could cause significant changes in bacterial diversity. Another possible reason is that the short duration of drug treatments used may have been insufficient to cause the corresponding changes. Further analysis of the species composition of each treatment group showed that after CAM treatment, *Prevotella* had the highest proportion and became the dominant genus, while the abundance of *Megasphaera* decreased. Studies have shown that a high proportion of *Prevotella* is associated with chronic intestinal inflammation (Ley, 2016) and *Megasphaera* can produce short-chain fatty acids that are beneficial to human health (Cuesta-Zuluaga et al., 2017), indicating damage to the intestinal flora of the CAM group. It was also reported that AMX could decrease the abundance of *Clostridium coccoides* and *Eubacterium rectale* while increasing the abundance of *Enterobacteriaceae* and the proportion of *Bacteroides* (Barc et al., 2004; Panda et al., 2014). However, there was no significant change in the abundance of these bacteria in this study, possibly because the *in vivo* environment was more complex than the *in vitro* conditions. The internal environment is affected by diet, gastrointestinal diseases, previous drug treatment, individual differences in drug absorption rate and other factors, all of which can have an impact on the therapeutic effect of antibiotics (Oh et al., 2016). The antibacterial activity of fatty acids is relatively broad spectrum.
Whereas, in our study, LipoLLA have little effect on intestinal flora in vitro. This may be related to the selectivity of fatty acids. Different fatty acids may have effects on different bacteria (Desbois and Smith, 2010).

In summary, this study indicated that LipoLLA had an antibacterial effect on H. pylori strains in vitro, exhibiting a synergistic or additive effect when combined with common anti-H. pylori drugs. The mechanism of action of LipoLLA against H. pylori involved destruction of the outer membrane barrier of bacteria, which made it difficult for bacteria to develop drug resistance. In addition, this study found that LipoLLA had no significant effect on the intestinal flora in vitro, providing preliminarily a basic guarantee for the safety of LipoLLA.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/sra/PRJNA814527, accession number: PRJNA814527.

ETHICS STATEMENT

The research protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (IRB 2018-116 and IRB 2014-032). The participant provided written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

Barc, M. C., Bourlioux, F., Rigottier-Gois, L., Charrin-Sarnel, C., Janoir, C., Bourreau, H., et al. (2004). Effect of Aminocillin-Clavulanic Acid on Human Fecal Flora in a Gnotobiotic Mouse Model Assessed With Fluorescence Hybridization Using Group-Specific 16s rRNA Probes in Combination With Flow Cytometry. Antimicrob. Agents Chemother. 48 (4), 1365–1368. doi: 10.1128/AAC.48.4.1365-1368.2004

Cockerill, F. (2012). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement [Provides Updated Tables for M02-A11 and M07-A9] (Wayne, PA: Clinical and Laboratory Standards Institute).

Cuesta-Zuluaga, J. D. L., Mueller, N. T., Corrales-Aguedo, V., Velazquez-Mejia, E. P., and Escobar, J. S. (2017). Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia Muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care 40 (1), 54–62. doi: 10.2337/dc16-1324

Desbois, A. P., and Smith, V. J. (2010). Antibacterial Free Fatty Acids: Activities, Mechanisms of Action and Biotechnological Potential. Appl. Microbiol. Biot. 85 (6), 1629–1642. doi: 10.1007/s00253-009-2355-3

Flores-Treviño, S., Mendoza-Olazárrain, S., Bocanegra-Ibarias, P., Maldonado-Garza, H. J., and Garza-González, E. (2018). Helicobacter Pylori Drug Resistance: Therapy Changes and Challenges. Expert Rev. Gastroent. 12 (8), 819–827. doi: 10.1080/17474124.2018.1496017

Ford, A. C., Gurusamy, K. S., Delaney, B., Forman, D., and Mosayyedi, P. (2016). Eradication Therapy for Peptic Ulcer Disease in Helicobacter Pylori-Positive People. Cochrane Database Syst. Rev. 4, D3840. doi: 10.1002/14651858. CD003840.pub5

AUTHOR CONTRIBUTIONS

YX and YF designed the study. YW and SW acquired and analyzed the data, drafted the manuscript. LW, YW, and DL revised contents critically. All authors contributed to the article and approved the submitted version.

FUNDING

Funding was provided by grants from the National Natural Science Foundation of China (No. 81970502, No. 81860107, No.82060109), the Science and Technology Projects of Jiangxi Province (20203BGC73051), Science and technology research project of education department of Jiangxi province in 2018(GJJ180047), and the supervision project of Jiangxi Provincial Drug Administration (2020J516).

ACKNOWLEDGMENTS

We thank the Sino German Joint Research Institute and the State Key Laboratory of Food Science and Technology of Nanchang University for the probiotics culture technology.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.865320/full#supplementary-material

Graham, D. Y., Lu, H., and Yamaoka, Y. (2007). A Report Card to Grade Helicobacter Pylori Therapy. Helicobacter 12, 275–278. doi: 10.1111/j.1523-5378.2007.00518.x

Isenberg, H. D. (1992). “Synergism Testing: Broth Microdilution Checkerboard and Broth Macrodilution Methods,” in: Clinical Microbiology Procedures Handbook, 2th Edition Ed. H. D. Isenberg (Washington DC: American Society Microbiology), 1–28.

Hooi, J., Lai, W. Y., Ng, W. K., Suen, M., Underwood, F. E., Tanyingoh, D., et al. (2017). Global Prevalence of Helicobacter Pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 153 (2), 420–429. doi: 10.1053/j.gastro.2017.04.022

Hsu, P. I., Pan, C. Y., Kao, J. Y., Tsay, F. W., Peng, N. J., Kao, S. S., et al. (2018). Helicobacter Pylori Eradication With Bismuth Quadruple Therapy Leads to Dysbiosis of Gut Microbiota With an Increased Relative Abundance of Proteobacteria and Decreased Relative Abundances of Bacteroidetes and Actinobacteria. Helicobacter 23 (4), e12498. doi: 10.1111/hel.12498

Ianiro, G., Tilg, H., and Gasbarrini, A. (2016). Antibiotics as Deep Modulators of Gut Microbiota: Between Good and Evil. Gut 65 (11), 1906–1915. doi: 10.1136/gutjnl-2016-312297

Jackson, M. A., Goodrich, J. K., Maxan, M. E., Freedberg, D. E., Abrams, J. A., Poole, A. C., et al. (2016). Proton Pump Inhibitors Alter the Composition of the Gut Microbiota. Gut 65 (5), 749–756. doi: 10.1136/gutjnl-2015-310861

Jakobsson, H. E., Jernberg, C., Andersson, A. F., Sjolund-Karlsson, M., Jansson, J. K., and Engstrand, L. (2010). Short-Term Antibiotic Treatment has Differing Long-Term Impacts on the Human Throat and Gut Microbiome. PloS One 5 (3), e9836. doi: 10.1371/journal.pone.0009836

Jung, S. W., and Lee, S. W. (2016). The Antibacterial Effect of Fatty Acids on Helicobacter Infection. Kor. J. Intern. Med. 31 (1), 30–35. doi: 10.3904/kijm.2016.31.1.30
Jung, S. W., Thamphiwatana, S., Zhang, L., and Obonyo, M. (2015). Mechanism of Antibacterial Activity of Liposomal Linolenic Acid Against Helicobacter Pylori. PLoS One 10 (3), e16519. doi: 10.1371/journal.pone.016519

Langdon, A., Crook, N., and Dantas, G. (2016). The Effects of Antibiotics on the Microbiome Through Development and Alternative Approaches for Therapeutic Modulation. Genome Med. 8 (1), 39. doi: 10.1186/s13073-016-0294-z

Ley, R. E. (2016). Gut Microbiota in 2015: Prevotella in the Gut: Choose Carefully. Nat. Rev. Gastroenterol. Hepatol. 13 (2), 69–70. doi: 10.1038/ntrsgastro.2016.4

Li, X. X., Shi, S., Rong, L., Feng, M. Q., and Zhong, L. (2018). The Impact of Liposomal Linolenic Acid on Gastrointestinal Microbiota in Mice. Int. J. Nanomed. 13, 1399–1409. doi: 10.2147/IJNN.S151825

Liu, W. Z., Xie, Y. L., Hu, H., Cheng, H., Zeng, Z. B., Zhou, L. Y., et al. (2018). Fifth Chinese National Consensus Report on the Management of Helicobacter Pylori Infection. Helicobacter 23 (2), e12475. doi: 10.1111/hel.12475

Maiertheiner, P., Megraud, C. A., Gisbert, J. P., Kuipers, E. J., Axon, L. Y., et al. (2018). Fifth Chinese National Consensus Report on the Management of Helicobacter Pylori Infection-The Maastricht V/Florence Consensus Report. Gut 66 (1), 6–30. doi: 10.1136/gutjnl-2016-312288

Moayedi, P. M., Lacy, B. E., Andrews, C. N., Enns, R. A., Howden, C. W., and Vakil, N. (2017). Corrigendum: ACG and CAG Clinical Guideline: Management of Dyspepsia. Am. J. Gastroenterol. 112 (9), 1484. doi: 10.1038/ajg.2017.238

Obonyo, M., Zhang, L., Thamphiwatana, S., Pornpattananangkul, D., Fu, V., and Zhang, L. (2012). Antibacterial Activities of Liposomal Linolenic Acids Against Antibiotic-Resistant Helicobacter Pylori. Mol. Pharm. 9 (9), 2677–2685. doi: 10.1021/mp300243w

Odds, F. C. (2003). Synergy, Antagonism, and What the Chequerboard Puts Between Them. J. Antimicrob. Chemother. 52 (1), 1. doi: 10.1093/jac/dkg301

Oh, B., Kim, B., Kim, J. W., Kim, J. S., Koh, S., Kim, B. G., et al. (2016). The Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication: Randomized Controlled Trial. Helicobacter 21 (3), 165–174. doi: 10.1111/hel.12270

Panda, S., El, K. I., Casellas, F., Lopez, V. J., Garcia, C. M., Santiago, A., et al. (2014). Short-Term Effect of Antibiotics on Human Gut Microbiota. PloS One 9 (4), e95476. doi: 10.1371/journal.pone.0095476

Petschow, B. W., Batema, R. P., and Ford, L. L. (1996). Susceptibility of Helicobacter Pylori to Bactericidal Properties of Medium-Chain Monoglycerides and Free Fatty Acids. Antimicrob. Agents Chemother. 40 (2), 302–306. doi: 10.1128/AAC.40.2.302

Raz, E., P. A., Carrara, E., Graham, D. Y., Conti, M., and Tacconelli, E. (2018). Prevalence of Antibiotic Resistance in Helicobacter Pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions. Gastroenterology 155 (5), 1372–1382. doi: 10.1053/j.gastro.2018.07.007

Schlaermann, P., Toelle, B., Berger, H., Schmidt, S. C., Glanemann, M., Ordemann, J., et al. (2016). A Novel Human Gastric Primary Cell Culture System for Modelling Helicobacter Pylori Infection In Vitro. Gut 65 (2), 202–213. doi: 10.1136/gutjnl-2014-307949

Shang, D., Liu, Y., Jiang, F., Ji, F., Wang, H., and Han, X. (2019). Synergistic Antibacterial Activity of Designed Trp-Containing Antibacterial Peptides in Combination With Antibiotics Against Multidrug-Resistant Staphylococcus Epidermidis. Front. Microbiol. 10, 2719. doi: 10.3389/fmicb.2019.02719

Song, Z., Zhou, L., Zhang, J., He, L., Bai, P., and Xue, Y. (2016). Hybrid Therapy as First-Line Regimen for Helicobacter Pylori Eradication in Populations With High Antibiotic Resistance Rates. Helicobacter 21 (5), 382–388. doi: 10.1111/hel.12294

Tariq, H., Patel, H., Kamal, M. U., Abbas, N., Ameen, M., Azam, S., et al. (2020). Reevaluation of the Efficacy of First Line Regimen for Helicobacter Pylori. Clin. Exp. Gastroenterol. 13, 25–33. doi: 10.2147/CEG.S39343

Thamphiwatana, S., Gao, W., Obonyo, M., and Zhang, L. (2014). In Vivo Treatment of Helicobacter Pylori Infection With Liposomal Linolenic Acid Reduces Colonization and Ameliorates Inflammation. Proc. Natl. Acad. Sci. U. S. A. 111 (49), 17600–17605. doi: 10.1073/pnas.1418230111

Zhang, Y. (2015). Primary Antibiotic Resistance Of Helicobacter Pylori Strains Isolated From Patients With Dyspeptic Symptoms in Beijing: A Prospective Serial Study. World J. Gastroenterol. 21 (9), 2786. doi: 10.3748/wjg.v21.i9.2786

Zhang, X., Jiang, A., Yu, H., Xiong, Y., Zhou, G., Qin, M., et al. (2016). Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter Pylori by Increasing Cell Permeability. Molecules 21 (11), 1435. doi: 10.3390/molecules21111435

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Wu, Wang, Wang, Liu, Fu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.